---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-000946"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T13:49:33.005935+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)

## Summary
- Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.
- 15N-ureagenesis function (RUF) increased from 29.0% baseline to 43.7% at day 28 post-fifth dose (p=0.026).
- Ammonia remained stable and within normal range in both studies; one hyperammonemia event on placebo.
- ARCT-810 safe and well tolerated across Phase 1/2 with no serious infusion reactions on optimized 3-hour regimen.

## SEC filing metadata
- accession: 0001193805-25-000946
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380525000946/0001193805-25-000946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380525000946/e664658_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-000946
- JSON: https://secwatch.observer/filing/0001193805-25-000946.json
- Plain text: https://secwatch.observer/filing/0001193805-25-000946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.